agreed with clyde here
SC as chair is good and Joseph as a director is good, there's still an independant director to be positioned so that oversight of corporate governance can be maintained.
Nothing much is going to happen until the release of Ph3 trial results in late Dec or early Jan - so we just need to wait
I think that SC is re-positioning this Co. for growth
